Plain-English translation of NCT02781883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called BP1001 in combination with two existing drugs (venetoclax and decitabine) to treat acute myeloid leukemia (AML), a serious blood cancer. The new medication works by blocking a protein that helps cancer cells grow and divide. Researchers believe this combination might help patients whose condition is newly diagnosed, relapsed, or resistant to other treatments.
Most patients with AML who receive standard intensive chemotherapy eventually relapse unless they undergo a bone marrow transplant—a very difficult procedure. This trial exists to find a gentler but effective treatment option for patients who are too sick, too old, or have other medical reasons that make intensive chemotherapy too dangerous.
You likely qualify if…
You likely don't qualify if…
You will receive infusions or tablets of the medication at a hospital or clinic, likely on a regular schedule over several weeks or months. Your doctors will monitor your health closely with blood tests and check-ups to see how well the treatment is working and watch for any side effects. The exact schedule will depend on which group you are in (newly diagnosed or relapsed/resistant disease), but you should expect regular clinic visits and lab work throughout the trial.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States